



Progesterone Receptor Ab-6 (Clone hPRa 6)

Mouse Monoclonal Antibody

Cat. #DLN-08320 (0.1ml at 200µg/ml) (Purified Ab with BSA and Azide)

Cat. #DLN-08320, DLN-08321, or DLN-08319 (0.1ml, 0.5ml, or 1.0ml at 200µg/ml) (Purified Ab with BSA and Azide)

Cat. #DLN-08322 or DLN-08323 (0.1ml or 0.2ml at 1.0mg/ml) (Purified Ab without BSA and Azide)

Description: Human PgR exists in two forms: 116kDa (B-form) and 81kDa (A-form). It acts as ligand activated transcription factor to regulate expression of the target genes. Null mutation in PgR gene leads to pleiotrophic reproductive abnormalities.

Comments: Ab-6 preferentially reacts with B-form of progesterone receptor.

Mol. Wt. of Antigen: 116kDa (triplet, B-form)

Epitope: Not determined

Species Reactivity: Human, Cow, Rabbit, and Chicken. Does not react with monkey. Others-not known.

Clone Designation: hPRa 6

Ig Isotype: IgG_{2b}

Immunogen: Partially purified PgR from a human endometrial carcinoma (EnCa 101) grown in athymic mice.

Applications and Suggested Dilutions:

- Immunofluorescence
- Immunoprecipitation (Native and denatured)
(Use Protein A; Ab at 2µg/mg protein lysate)
- Sedimentation in Sucrose Gradient¹
- Western Blotting (Not optimum)
- Immunohistology

The optimal dilution for a specific application should be determined by the investigator.

Positive Control: T47D cells

Cellular Localization: Nuclear

Supplied As: 200µg/ml of antibody purified from ascites fluid by Protein A chromatography. Prepared in 10mM PBS, pH 7.4, with 0.2% BSA and 0.09% sodium azide. Also available without BSA and azide at 1mg/ml.

Storage and Stability:

Ab with sodium azide is stable for 24 months when stored at 2-8°C. Antibody WITHOUT sodium azide is stable for 36 months when stored at below 0°C.

dianova GmbH

Warburgstr. 45 • 20354 Hamburg

Telefon (040)45067-0 • Telefax (040) 45067-490 • www.dianova.de



Progesterone Receptor Ab-6 (Clone hPRa 6)

Mouse Monoclonal Antibody

Cat. #DLN-08320 (0.1ml at 200µg/ml) (Purified Ab with BSA and Azide)

Cat. #DLN-08320, DLN-08321, or DLN-08319 (0.1ml, 0.5ml, or 1.0ml at 200µg/ml) (Purified Ab with BSA and Azide)

Cat. #DLN-08322 or DLN-08323 (0.1ml or 0.2ml at 1.0mg/ml) (Purified Ab without BSA and Azide)

Key References:

1. Clarke CL, *et. al.* Endocrinology, 1987, 121(3):1123-32.

Limitations and Warranty:

This product has been given a limited license by Abott laboratories under U.S. Patent No. 4,742,000 and foreign equivalents for research purposes only. Should the purchaser of the product intend to use it for any other purposes than research, they should contact Abott Laboratories about obtaining the appropriate license. Our products are intended FOR RESEARCH USE ONLY and are not approved for clinical diagnosis, drug use or therapeutic procedures. No products are to be construed as a recommendation for use in violation of any patents. We make no representations, warranties or assurances as to the accuracy or completeness of information provided on our data sheets and website. Our warranty is limited to the actual price paid for the product. Dianova is not liable for any property damage, personal injury, time or effort or economic loss caused by our products.

Material Safety Data:

This product is not licensed or approved for administration to humans or to animals other than the experimental animals. Standard Laboratory Practices should be followed when handling this material. The chemical, physical, and toxicological properties of this material have not been thoroughly investigated. Appropriate measures should be taken to avoid skin and eye contact, inhalation, and ingestion. The material contains 0.09% sodium azide as a preservative. Although the quantity of azide is very small, appropriate care should be taken when handling this material as indicated above. The National Institute of Occupational Safety and Health has issued a bulletin citing the potential explosion hazard due to the reaction of sodium azide with copper, lead, brass, or solder in the plumbing systems. Sodium azide forms hydrazoic acid in acidic conditions and should be discarded in a large volume of running water to avoid deposits forming in metal drainage pipes.

For Research Use Only

dianova GmbH

Warburgstr. 45 • 20354 Hamburg

Telefon (040)45067-0 • Telefax (040) 45067-490 • www.dianova.de



Progesterone Receptor Ab-6 (Clone hPRa 6)

Mouse Monoclonal Antibody

Cat. #DLN-08320 (0.1ml at 200µg/ml) (Purified Ab with BSA and Azide)

Cat. #DLN-08320, DLN-08321, or DLN-08319 (0.1ml, 0.5ml, or 1.0ml at 200µg/ml) (Purified Ab with BSA and Azide)

Cat. #DLN-08322 or DLN-08323 (0.1ml or 0.2ml at 1.0mg/ml) (Purified Ab without BSA and Azide)

References Describing The Use of DIANOVA' Progesterone Receptor MAb's of hPRa Series:

1. Satyaswaroop PG. Development of a preclinical model for hormonal therapy of human endometrial carcinomas. *Annals of Medicine*, 1993, 25:105-11.
2. Shyamala G; Schweitzer M; Ullrich SJ. Relationship between 90-kilodalton heat shock protein, estrogen receptor, and progesterone receptor in human mammary tumors. *Breast Cancer Research and Treatment*, 1993, 26(1):95-100.
3. Satyaswaroop PG; Clarke CL; Zaino RJ; Mortel R. Apparent resistance in human endometrial carcinoma during combination treatment with tamoxifen and progestin may result from desensitization following downregulation of tumor progesterone receptor. *Cancer Letters*, 1992, 62(2):107-14.
4. Clarke CL; Graham J; Roman SD; Sutherland RL. Direct transcriptional regulation of the progesterone receptor by retinoic acid diminishes progestin responsiveness in the breast cancer cell line T-47D. *Journal of Biological Chemistry*, 1991 Oct 5, 266(28):18969-75.
5. Schneider W; Ramachandran C; Satyaswaroop PG; Shyamala G. Murine progesterone receptor exists predominantly as the 83-kilodalton 'A' form. *Journal of Steroid Biochemistry and Molecular Biology*, 1991, 38(3):285-91.
6. Mortel R; Zaino RJ; Satyaswaroop PG. Designing a schedule of progestin administration in the control of endometrial carcinoma growth in the nude mouse model. *American Journal of Obstetrics and Gynecology*, 1990, 162(4):928-34; discussion 934-6.
7. Clarke CL; Roman SD; Graham J; Koga M; Sutherland RL. Progesterone receptor regulation by retinoic acid in the human breast cancer cell line T-47D. *Journal of Biological Chemistry*, 1990 Jul 25, 265(21):12694-700.
8. 10. Clarke CL. Cell-specific regulation of progesterone receptor in the female reproductive system. *Molecular and Cellular Endocrinology*, 1990 May 7, 70(3):C29-33.
9. Satyaswaroop PG; Mortel R. Hormonal treatment of endometrial carcinoma: an overview and new development in biology. *Journal of Steroid Biochemistry and Molecular Biology*, 1990, 37(6):997-1001.
10. Shyamala G; Schneider W; Schott D. Developmental regulation of murine mammary progesterone receptor gene expression. *Endocrinology*, 1990 Jun, 126(6):2882-9.
11. Alexander IE; Clarke CL; Shine J; Sutherland RL. Progestin inhibition of progesterone receptor gene expression in human breast cancer cells. *Molecular Endocrinology*, 1989 Sep, 3(9):1377-86.
12. Feil PD; Clarke CL; Satyaswaroop PG. A polyclonal antiserum against the rabbit progesterone receptor recognizes the human receptor: biochemical characterization. *Cell Biochemistry and Function*, 1989, 7(2):139-46.
13. Satyaswaroop PG; Zaino RJ; Mortel R. Carcinoma of the endometrium and hormonal receptors. *Cancer Treatment and Research*, 1989, 49:71-92.
14. Tabibzadeh SS; Satyaswaroop PG. Sex steroid receptors in lymphoid cells of human endometrium. *American Journal of Clinical Pathology*, 1989, 91(6):656-63.
15. Zaino RJ; Clarke CL; Feil PD; Satyaswaroop PG. Differential distribution of estrogen and progesterone receptors in rabbit uterus detected by dual immunofluorescence. *Endocrinology*, 1989, 125(5):2728-34.
16. Feil PD; Clarke CL; Satyaswaroop PG. Progesterone receptor structure and protease activity in primary human endometrial carcinoma. *Cancer Research*, 1988, 48(5):1143-7.
17. Feil PD; Clarke CL; Satyaswaroop PG. Progestin-mediated changes in progesterone receptor forms in the normal human endometrium. *Endocrinology*, 1988, 123(5):2506-13.
18. Gray GO; Satyaswaroop PG. Species crossreactivity of human progesterone receptor monoclonal antibodies: Western blot analysis. *Biochemical and Biophysical Research Communications*, 1988, 157(3):1067-77.
19. Zaino RJ; Clarke CL; Mortel R; Satyaswaroop PG. Heterogeneity of progesterone receptor distribution in human endometrial adenocarcinoma. *Cancer Research*, 1988, 48(7):1889-95.
20. Clarke CL; Feil PD; Satyaswaroop PG. Progesterone receptor regulation by 17 beta-estradiol in human endometrial carcinoma grown in nude mice. *Endocrinology*, 1987, 121(5):1642-8.
21. Clarke CL; Zaino RJ; Feil PD; Miller JV; Steck ME; Ohlsson-Wilhelm BM; Satyaswaroop PG. Monoclonal antibodies to human progesterone receptor: characterization by biochemical and immunohistochemical techniques. *Endocrinology*, 1987, 121(3):1123-32.

dianova GmbH

Warburgstr. 45 • 20354 Hamburg

Telefon (040)45067-0 • Telefax (040) 45067-490 • www.dianova.de